Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Cash & Current Investments (2016 - 2025)

Lipocine's Cash & Current Investments history spans 14 years, with the latest figure at $15.1 million for Q3 2025.

  • For Q3 2025, Cash & Current Investments fell 57.86% year-over-year to $15.1 million; the TTM value through Sep 2025 reached $15.1 million, down 57.86%, while the annual FY2024 figure was $15.4 million, 60.67% down from the prior year.
  • Cash & Current Investments reached $15.1 million in Q3 2025 per LPCN's latest filing, down from $17.9 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $65.6 million in Q3 2022 to a low of $15.1 million in Q3 2025.
  • Average Cash & Current Investments over 5 years is $35.9 million, with a median of $36.3 million recorded in 2022.
  • Peak YoY movement for Cash & Current Investments: surged 191.02% in 2021, then plummeted 69.85% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $44.7 million in 2021, then skyrocketed by 37.59% to $61.5 million in 2022, then tumbled by 36.18% to $39.2 million in 2023, then tumbled by 60.67% to $15.4 million in 2024, then fell by 1.92% to $15.1 million in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Cash & Current Investments are $15.1 million (Q3 2025), $17.9 million (Q2 2025), and $36.1 million (Q1 2025).